DMK Pharmaceuticals Corporation, along with its affiliates, filed a motion for joint administration of their Chapter 11 bankruptcy cases in the US Bankruptcy Court on February 2, 2024. As per the motion, the debtor seeks the joint administration of the cases of its affiliates, U.S. Compounding, Inc., Rhombus Pharmaceuticals Corporation, Biosyn, Inc. and Adamis Corporation, with its own case for administrative and procedural purposes. DMK Pharmaceuticals Corporation has been proposed as the lead debtor.
Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.035 USD | 0.00% | -30.00% | -95.00% |
Apr. 11 | North American Morning Briefing : Stock Futures Edge Lower Ahead of PPI Inflation Gauge | DJ |
Apr. 04 | North American Morning Briefing : Focus Turns to -2- | DJ |
1st Jan change | Capi. | |
---|---|---|
-95.00% | 353K | |
+26.02% | 661B | |
+27.20% | 566B | |
-6.44% | 352B | |
+20.57% | 332B | |
+3.64% | 283B | |
+14.32% | 231B | |
+5.18% | 200B | |
-9.00% | 195B | |
-4.91% | 145B |
- Stock Market
- Equities
- DMKPQ Stock
- News DMK Pharmaceuticals Corporation
- Motion for Joint Administration Filed by DMK Pharmaceuticals Corporation